News coverage about NeuroMetrix (NASDAQ:NURO) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. NeuroMetrix earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave media coverage about the medical device company an impact score of 45.8156764579773 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
NeuroMetrix (NASDAQ:NURO) traded down 1.41% during trading on Friday, reaching $2.10. The company had a trading volume of 215,775 shares. NeuroMetrix has a 12 month low of $1.66 and a 12 month high of $13.84. The company’s market capitalization is $4.46 million. The firm’s 50 day moving average is $2.02 and its 200-day moving average is $1.70.
NeuroMetrix (NASDAQ:NURO) last posted its earnings results on Thursday, July 20th. The medical device company reported ($2.49) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.83) by $0.34. The firm had revenue of $4.31 million for the quarter, compared to the consensus estimate of $4.40 million. NeuroMetrix had a negative net margin of 83.92% and a negative return on equity of 209.56%. On average, equities analysts expect that NeuroMetrix will post ($11.20) earnings per share for the current year.
NURO has been the topic of several recent analyst reports. Zacks Investment Research lowered NeuroMetrix from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. ValuEngine lowered NeuroMetrix from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, HC Wainwright set a $16.00 price target on NeuroMetrix and gave the company a “buy” rating in a research note on Thursday, June 15th.
NeuroMetrix Company Profile
NeuroMetrix, Inc is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests.
Receive News & Ratings for NeuroMetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
